Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Biophytis SA (ALBPS) Stock Price & Analysis

ALBPS Stock Chart & Stats

€0.03-€0.00(-9.09%)
At close: 5:30 PM GMT+1
EUR 0.05EUR 0.13 Aug17 Aug31 Aug14 Sep28 Sep12 Oct26 Oct
Day’s Range
EUR 0.03 - EUR 0.03
52-Week Range
EUR 0.01 - EUR 0.16
Previous Close
EUR 0.03
Volume
1.91M
Average Volume (3M)
12.77M
Market Cap
EUR 11.52M
Enterprise Value
EUR 9.05M
Total Cash (Recent Filing)
EUR 1.21M
Total Debt (Recent Filing)
EUR 7.77M
Price to Earnings (P/E)
―
Beta
1.27
Next Earnings
Sep 10, 2027 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Focused Clinical-stage Specialization

Specialization in age-related diseases and muscle-function therapeutics indicates a focused R&D strategy and domain expertise. A concentrated pipeline can create differentiated assets, streamline trial design and partner appeal, supporting durable value creation if clinical progress continues.

Improving Loss And Cash-burn Trends

Material narrowing of losses and reduced cash outflows in 2024 signals better cost control and operational discipline. Sustained improvements enhance runway and lower near-term financing pressure, increasing the company’s ability to reach clinical inflection points before further dilution.

Partial Debt Reduction Since 2022

Measured reduction in debt improves balance-sheet flexibility and reduces leverage risk versus earlier peaks. Lower gross debt enhances negotiating leverage with partners and lenders and modestly reduces fixed financing costs, helping preserve cash for critical R&D activities.

Bears Say

No Revenue Over Multiple Years

Absence of product revenue across multiple years means the company lacks operating cash generation and remains fully reliant on financing or partners. This structural revenue gap increases execution risk and constrains long-term sustainability until commercialization or licensing occurs.

Deeply Negative Shareholders' Equity

Deep negative equity signals cumulative losses that impair solvency metrics and limit traditional financing options. Structural equity deficits can force dilutive recapitalizations or restrictive creditor terms, reducing strategic flexibility over the medium term.

Persistent Cash Burn And Funding Dependence

Consistent negative operating and free cash flow create ongoing dependency on external financing. Even with 2024 improvement, the structural need for capital raises heightens dilution risk, constrains multi-year planning, and may delay or complicate advancement of pivotal clinical programs.

Biophytis SA News

ALBPS FAQ

What was Biophytis SA’s price range in the past 12 months?
Biophytis SA lowest stock price was €0.01 and its highest was €0.16 in the past 12 months.
What is Biophytis SA’s market cap?
Biophytis SA’s market cap is €11.52M.
When is Biophytis SA’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Biophytis SA’s earnings last quarter?
Biophytis SA released its earnings results on Oct 30, 2025. The company reported -€0.18 earnings per share for the quarter.
Is Biophytis SA overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Biophytis SA pay dividends?
Biophytis SA does not currently pay dividends.
What is Biophytis SA’s EPS estimate?
Biophytis SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Biophytis SA have?
Biophytis SA has 373,875,400 shares outstanding.
What happened to Biophytis SA’s price movement after its last earnings report?
Biophytis SA reported an EPS of -€0.18 in its last earnings report. Following the earnings report the stock price went down -21.212%.
Which hedge fund is a major shareholder of Biophytis SA?
Currently, no hedge funds are holding shares in FR:ALBPS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology